1-6 of 6
Peter Savas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Peter Schmid, Nicholas C. Turner, Carlos H. Barrios, Steven J. Isakoff, Sung-Bae Kim, Marie-Paule Sablin, Shigehira Saji, Peter Savas, Gregory A. Vidal, Mafalda Oliveira, Joyce O'Shaughnessy, Antoine Italiano, Enrique Espinosa, Valentina Boni, Shane White, Beatriz Rojas, Ruffo Freitas-Junior, Yeesoo Chae, Igor Bondarenko, Jieun Lee, Cesar Torres Mattos, Jorge Luis Martinez Rodriguez, Lisa H. Lam, Surai Jones, Sarah-Jayne Reilly, Xiayu Huang, Kalpit Shah, Rebecca Dent
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 767–778.
https://doi.org/10.1158/1078-0432.CCR-23-2084
Published: 16 February 2024
View article titled, First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Open the PDF for First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results in another window
Includes: Supplementary data
Journal Articles

Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Jennifer Mooi, Fiona Chionh, Peter Savas, Jessica Da Gama Duarte, Geoffrey Chong, Stephen Brown, Rachel Wong, Timothy J. Price, Alysson Wann, Effie Skrinos, John M. Mariadason, Niall C. Tebbutt
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2159–2167.
https://doi.org/10.1158/1078-0432.CCR-20-2714
Published: 15 April 2021
View article titled, Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Open the PDF for Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study in another window
Includes: Supplementary data
Journal Articles

Metastatic Breast Cancer: TIL it is Too Late

Peter Savas, Sherene Loi
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 526–528.
https://doi.org/10.1158/1078-0432.CCR-19-3490
Published: 03 February 2020
View article titled, Metastatic Breast Cancer: TIL it is Too Late
Open the PDF for Metastatic Breast Cancer: TIL it is Too Late in another window
Journal Articles

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Imran G. House, Peter Savas, Junyun Lai, Amanda X.Y. Chen, Amanda J. Oliver, Zhi L. Teo, Kirsten L. Todd, Melissa A. Henderson, Lauren Giuffrida, Emma V. Petley, Kevin Sek, Sherly Mardiana, Tuba N. Gide, Camelia Quek, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Sherene Loi, Phillip K. Darcy, Paul A. Beavis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (2): 487–504.
https://doi.org/10.1158/1078-0432.CCR-19-1868
Published: 15 January 2020
View article titled, Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Open the PDF for Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1437.
https://doi.org/10.1158/1078-0432.CCR-18-4264
Published: 15 February 2019
View article titled, Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Journal Articles

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1499–1509.
https://doi.org/10.1158/1078-0432.CCR-15-1125
Published: 14 March 2016
View article titled, RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Open the PDF for RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors in another window
Includes: Supplementary data